Exelixis (NASDAQ:EXEL) managed to stay afloat and traded higher with an addition of 0.03 point or 0.41% at $7.41. The money flow data is a negative $(-1.28) million with $2.83 million in upticks and $4.11 million in downticks. The intraday up/down ratio came in at 0.69. The shares have seen 12.44% change for the week in its share price.From the data available, it was found that a block transaction occurred during the course of trading. For it, the aggregated worth of the upticks was $0.2 million and the combined worth of the downticks was $0.71, Million, leading to the up/down ratio of 0.29. The block trade saw a net money flow of $(-0.5) million.
Currently the company Insiders own 5.9% of Exelixis shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by 11.81% . Institutional Investors own 77.15% of Exelixis shares. During last six month period, the net percent change held by insiders has seen a change of 11.81%. On the companys insider trading activities, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the director of Exelixis, Inc., Willsey Lance, had purchased 60,000 shares in a transaction dated on May 9, 2016. The transaction was executed at $4.96 per share with total amount equaling $297,600.
Exelixis (NASDAQ:EXEL) witnessed a volatile trading activity on Monday and eventually ended flat at 0% or 0 points without letting the bulls or bears take much advantage. The trading began at $7.31 and reached the intraday high at $7.44. The bulls started the profit booking and pushed the shares to intraday low of $7.25. The trading session was marked by a volume range of 4,987,817 shares exchanging hands. The 52-week high of the shares is $7.49 and the 52-week low is $3.31. The market cap of the company stands at $1,688 million and there are 228,739,660 shares in public circulation.
Many analysts have stated their opinion on the company shares. Major Brokerage house, Stifel Nicolaus upgrades its ratings on Exelixis (NASDAQ:EXEL). According to the latest information available, the shares are now rated Buy by the analysts at the agency. Previously, the analysts had a Hold rating on the shares. The rating by the firm was issued on April 4, 2016.
Exelixis Inc. is a biopharmaceutical company. The Company is engaged in developing small molecule therapies for the treatment of cancer. The Company is focusing on resources development and commercialization of COMETRIQ (cabozantinib) for the treatment of progressive, metastatic medullary thyroid cancer (MTC) in the United States. The Companys other programs include metastatic renal cell carcinoma (mRCC), a phase III trial comparing cabozantinib to everolimus in patients with mRCC who have experienced disease progression following treatment with at least one prior VEGFR TKI; CELESTIAL, a phase III trial comparing cabozantinib with placebo in patients with advanced hepatocellular cancer (HCC) who have previously been treated with sorafenib; NSCLC (non-small cell lung cancer); mCRPC (metastatic castration-resistant prostate cancer) and XL888, a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90).